Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference
Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference Cambridge, Mass. – October 2, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
Toggle Summary Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research Cambridge, Mass. – September 24, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Niels
Toggle Summary Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates Cambridge, Mass. – September 20, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and
Toggle Summary Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference
Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference Cambridge, Mass. – September 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
Toggle Summary Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer
Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer Cambridge, MA – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John L.
Toggle Summary Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
Encouraging safety and biological activity supports advancement into phase 2 studies
Toggle Summary Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting
Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting CAMBRIDGE, MA – August 6, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it will present the
Toggle Summary Pharmaceutical Executive: Acceleron Pharma’s Pipeline Selected to Top 7 Most Exciting Future Therapies and Technologies
Pharmaceutical Executive: Acceleron Pharma’s Pipeline Selected to Top 7 Most Exciting Future Therapies and Technologies Pharmaceutical Executive, August 1, 2007
Toggle Summary Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference
Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference CAMBRIDGE, MA – July 31, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that company President and Founder, John Knopf, Ph.D., will provide a
Toggle Summary Boston Globe: Super-buff cattle may hold key to treating muscular diseases
Boston Globe: Super-buff cattle may hold key to treating muscular diseases Link to article